215 related articles for article (PubMed ID: 33619146)
1. Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis.
Kirby C; Herlihy D; Clarke L; Mullan R
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33619146
[TBL] [Abstract][Full Text] [Related]
2. Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy.
Christoforidou A; Goudakos J; Bobos M; Lefkaditis E; Vital V; Markou K
Am J Otolaryngol; 2013; 34(3):268-72. PubMed ID: 23357593
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
Dhaille F; Viseux V; Caudron A; Dadban A; Tribout C; Boumier P; Clabaut A; Lok C
Dermatology; 2010; 220(3):234-7. PubMed ID: 20185892
[TBL] [Abstract][Full Text] [Related]
4. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.
Massara A; Cavazzini L; La Corte R; Trotta F
Semin Arthritis Rheum; 2010 Feb; 39(4):313-9. PubMed ID: 19147181
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
[TBL] [Abstract][Full Text] [Related]
6. [Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review].
Javot L; Tala S; Scala-Bertola J; Massy N; Trenque T; Baldin B; Andréjak M; Gillet P; Petitpain N;
Therapie; 2011; 66(2):149-54. PubMed ID: 21635863
[TBL] [Abstract][Full Text] [Related]
7. Treatment of psoriatic arthritis with secukinumab: a case series.
Nicola S; Rolla G; Monti R; Brussino L
J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
[TBL] [Abstract][Full Text] [Related]
8. Possible autoimmune hemolytic anemia induced by secukinumab: a case report.
Rahman PA; Kalim H; Prawitasari S; Raharjo FM
Pan Afr Med J; 2022; 41():41. PubMed ID: 35317476
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab: A Review in Psoriatic Arthritis.
Shirley M; Scott LJ
Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB; Behrens F; Mease PJ; Kavanaugh A; Ritchlin C; Nash P; Masmitja JG; Goupille P; Korotaeva T; Gottlieb AB; Martin R; Ding K; Pellet P; Mpofu S; Pricop L;
Lancet; 2020 May; 395(10235):1496-1505. PubMed ID: 32386593
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
13. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
Rodríguez Moncada R; Vázquez Morón JM; Pallarés Manrique H
Rev Esp Enferm Dig; 2019 Sep; 111(9):720-721. PubMed ID: 31333036
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab for the treatment of psoriatic arthritis.
Baronaite Hansen R; Kavanaugh A
Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
Reich K; Warren RB; Coates LC; Di Comite G
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
[TBL] [Abstract][Full Text] [Related]
16. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.
Lu J; Tang S; Yu N; Yi X; Li Y
J Int Med Res; 2020 Nov; 48(11):300060520969494. PubMed ID: 33161790
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
[TBL] [Abstract][Full Text] [Related]
20. Death by antibody.
Faccini T; Dhesi Z; Shah S
BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31122953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
